Base de dados : MEDLINE
Pesquisa : G08.852.179 [Categoria DeCS]
Referências encontradas : 12169 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 1217 ir para página                         

  1 / 12169 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28845946
[Au] Autor:Yarovoi SK; Golovanov SA; Khaziakhmetova MR; Dzhalilov OV
[Ad] Endereço:N.A. Lopatkin Scientific Research Institute of Urology and Interventional Radiology branch of the NMRRC of Minzdrav of Russia, Moscow, Russia.
[Ti] Título:[Nephrolithiasis coexisting with type 2 diabetes: current concept of the features of stone formation and the effects of hypoglycemic therapy on lithogenesis].
[So] Source:Urologiia;(3):92-97, 2017 Jul.
[Is] ISSN:1728-2985
[Cp] País de publicação:Russia (Federation)
[La] Idioma:rus
[Ab] Resumo:The article analyzes Russian and international literature examining specific features of the pathogenesis of renal stones in the setting of carbohydrate metabolism disorders. The authors outline the renal effects of the main pharmacological groups of oral hypoglycemic drugs regarding metaphylaxis of nephrolithiasis. An increased risk of nephrolithiasis in type 2 diabetes mellitus is realized through hyperuricemia with concurrent urine acidification. Current literature is lacking studies on the effects of oral hypoglycemic drugs on urine properties. There are reports about the tendency of biguanides (metformin) to shift the urine reaction to the acid side. Derivatives of sulfonylureas, incretins and inhibitors of dipeptidyl peptidase-4, do not significantly affect the urinary acidity and urinary salt excretion. Inhibitors of sodium-glucose cotransporter type 2 (gliflozins) tend to reduce the blood level of urate, but the mechanism of this effect and the safety of these drugs in the setting of urolithiasis have not yet been investigated.
[Mh] Termos MeSH primário: Diabetes Mellitus Tipo 2/complicações
Diabetes Mellitus Tipo 2/tratamento farmacológico
Hipoglicemiantes/uso terapêutico
Nefrolitíase/tratamento farmacológico
Nefrolitíase/etiologia
[Mh] Termos MeSH secundário: Administração Oral
Diurese/efeitos dos fármacos
Intolerância à Glucose/complicações
Seres Humanos
Concentração de Íons de Hidrogênio
Hiperuricemia/complicações
Hipoglicemiantes/administração & dosagem
Hipoglicemiantes/farmacologia
Urina/química
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Hypoglycemic Agents)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171109
[Lr] Data última revisão:
171109
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170829
[St] Status:MEDLINE


  2 / 12169 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28768662
[Au] Autor:Ahmad A; Daneva Z; Li G; Dempsey SK; Li N; Poklis JL; Lichtman A; Li PL; Ritter JK
[Ad] Endereço:Department of Pharmacology and Toxicology, Virginia Commonwealth University School of Medicine, Richmond, Virginia.
[Ti] Título:Stimulation of diuresis and natriuresis by renomedullary infusion of a dual inhibitor of fatty acid amide hydrolase and monoacylglycerol lipase.
[So] Source:Am J Physiol Renal Physiol;313(5):F1068-F1076, 2017 Nov 01.
[Is] ISSN:1522-1466
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The renal medulla, considered critical for the regulation of salt and water balance and long-term blood pressure control, is enriched in anandamide and two of its major metabolizing enzymes, cyclooxygenase-2 (COX-2) and fatty acid amide hydrolase (FAAH). Infusion of anandamide (15, 30, and 60 nmol·min ·kg ) into the renal medulla of C57BL/6J mice stimulated diuresis and salt excretion in a COX-2- but not COX-1-dependent manner. To determine whether endogenous endocannabinoids in the renal medulla can elicit similar effects, the effects of intramedullary isopropyl dodecyl fluorophosphate (IDFP), which inhibits the two major endocannabinoid hydrolases, were studied. IDFP treatment increased the urine formation rate and sodium excretion in a COX-2- but not COX-1-dependent manner. Neither anandamide nor IDFP affected the glomerular filtration rate. Neither systemic (0.625 mg·kg ·30 min iv) nor intramedullary (15 nmol·min ·kg ·30 min ) IDFP pretreatment before intramedullary anandamide (15-30 nmol·min ·kg ) strictly blocked effects of anandamide, suggesting that hydrolysis of anandamide was not necessary for its diuretic effect. Intramedullary IDFP had no effect on renal blood flow but stimulated renal medullary blood flow. The effects of IDFP on urine flow rate and medullary blood flow were FAAH-dependent as demonstrated using FAAH knockout mice. Analysis of mouse urinary PGE concentrations by HPLC-electrospray ionization tandem mass spectrometry showed that IDFP treatment decreased urinary PGE These data are consistent with a role of FAAH and endogenous anandamide acting through a COX-2-dependent metabolite to regulate diuresis and salt excretion in the mouse kidney.
[Mh] Termos MeSH primário: Amidoidrolases/antagonistas & inibidores
Diurese
Inibidores Enzimáticos/farmacologia
Monoacilglicerol Lipases/antagonistas & inibidores
[Mh] Termos MeSH secundário: Amidoidrolases/metabolismo
Animais
Ácidos Araquidônicos/metabolismo
Ciclo-Oxigenase 2/metabolismo
Diurese/efeitos dos fármacos
Endocanabinoides/metabolismo
Medula Renal/efeitos dos fármacos
Medula Renal/metabolismo
Masculino
Camundongos Endogâmicos C57BL
Camundongos Knockout
Monoacilglicerol Lipases/metabolismo
Natriurese/efeitos dos fármacos
Natriurese/fisiologia
Alcamidas Poli-Insaturadas/metabolismo
Circulação Renal/fisiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Arachidonic Acids); 0 (Endocannabinoids); 0 (Enzyme Inhibitors); 0 (Polyunsaturated Alkamides); EC 1.14.99.- (Ptgs2 protein, mouse); EC 1.14.99.1 (Cyclooxygenase 2); EC 3.1.1.23 (Monoacylglycerol Lipases); EC 3.5.- (Amidohydrolases); EC 3.5.1.- (fatty-acid amide hydrolase); UR5G69TJKH (anandamide)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171114
[Lr] Data última revisão:
171114
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170804
[St] Status:MEDLINE
[do] DOI:10.1152/ajprenal.00196.2017


  3 / 12169 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28728476
[Au] Autor:Shah N; Madanieh R; Alkan M; Dogar MU; Kosmas CE; Vittorio TJ
[Ad] Endereço:St. Francis Hospital, The Heart Center ®, Center for Advanced Cardiac Therapeutics, Roslyn, NY, USA.
[Ti] Título:A perspective on diuretic resistance in chronic congestive heart failure.
[So] Source:Ther Adv Cardiovasc Dis;11(10):271-278, 2017 Oct.
[Is] ISSN:1753-9455
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Chronic congestive heart failure (CHF) is a complex disorder characterized by inability of the heart to keep up the demands on it, followed by the progressive pump failure and fluid accumulation. Although the loop diuretics are widely used in heart failure (HF) patients, both pharmacodynamic and pharmacokinetic alterations are thought to be responsible for diuretic resistance in these patients. Strategies to overcome diuretic resistance include sodium intake restriction, changes in diuretic dose and route of administration and sequential nephron diuretic therapy. In this review, we discuss the definition, prevalence, mechanism of development and management strategies of diuretic resistance in HF patients.
[Mh] Termos MeSH primário: Diurese/efeitos dos fármacos
Resistência a Medicamentos
Insuficiência Cardíaca/tratamento farmacológico
Hemodinâmica/efeitos dos fármacos
Rim/efeitos dos fármacos
Inibidores de Simportadores de Cloreto de Sódio e Potássio/uso terapêutico
[Mh] Termos MeSH secundário: Doença Crônica
Insuficiência Cardíaca/diagnóstico
Insuficiência Cardíaca/fisiopatologia
Seres Humanos
Rim/fisiopatologia
Fatores de Risco
Inibidores de Simportadores de Cloreto de Sódio e Potássio/efeitos adversos
Inibidores de Simportadores de Cloreto de Sódio e Potássio/farmacocinética
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Sodium Potassium Chloride Symporter Inhibitors)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171030
[Lr] Data última revisão:
171030
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170722
[St] Status:MEDLINE
[do] DOI:10.1177/1753944717718717


  4 / 12169 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28700473
[Au] Autor:Hunsicker O; Feldheiser A; Weimann A; Liehre D; Sehouli J; Wernecke KD; Spies C
[Ad] Endereço:aDepartment of Anesthesiology and Operative Intensive Care Medicine (CCM, CVK), Charité - Universitätsmedizin Berlin bLabor Berlin-Charité Vivantes Services GmbH cDepartment of Gynaecology, European Competence Center for Ovarian Cancer, Charité- University Medicine Berlin dCharité-University Medicine Berlin and SOSTANA GmbH Berlin, Berlin, Germany.
[Ti] Título:Diagnostic value of plasma NGAL and intraoperative diuresis for AKI after major gynecological surgery in patients treated within an intraoperative goal-directed hemodynamic algorithm: A substudy of a randomized controlled trial.
[So] Source:Medicine (Baltimore);96(28):e7357, 2017 Jul.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Data on early markers for acute kidney injury (AKI) after noncardiovascular surgery are still limited. This study aimed to determine the diagnostic value of plasma neutrophil-gelatinase-associated lipocalin (pNGAL) and intraoperative diuresis for AKI in patients undergoing major abdominal surgery treated within a goal-directed hemodynamic algorithm.This study is a post-hoc analysis of a randomized controlled pilot trial comparing intravenous solutions within a hemodynamic goal-directed algorithm based on the esophageal Doppler in patients undergoing epithelial ovarian cancer surgery. The diagnostic value of plasma NGAL obtained at ICU admission and intraoperative diuresis was determined with respect to patients already meeting AKI criteria 6 hours after surgery (AKI6h) and to all patients meeting AKI criteria at least once during the postoperative course (AKItotal). AKI was diagnosed by the definition of the Kidney Disease Improving Global Outcome (KDIGO) group creatinine criteria and was screened up to postoperative day 3. Receiver operating characteristic curves including a gray zone approach were performed.A total of 48 patients were analyzed. None of the patients had increased creatinine levels before surgery and 14 patients (29.2%) developed AKI after surgery. Plasma NGAL was predictive for AKI6h (AUCAKI6h 0.832 (95% confidence interval [CI], 0.629-0.976), P = .001) and AKItotal (AUCAKItotal 0.710 (CI 0.511-0.878), P = .023). The gray zones of pNGAL calculated for AKI6h and AKItotal were 210 to 245 and 207 to 274 ng mL, respectively. The lower cutoffs of the gray zone at 207 and 210 ng mL had a negative predictive value (NPV) (i.e., no AKI during the postoperative course) of 96.8% (CI 90-100) and 87.1% (CI 78-97), respectively. Intraoperative diuresis was also predictive for AKI6h (AUCAKI6h 0.742 (CI 0.581-0.871), P = .019) with a gray zone of 0.5 to 2.0 mL kg h. At the lower cutoff of the gray zone at 0.5 mL kg h, corresponding to the oliguric threshold, the NPV was 84.2% (78-92).This study indicates that pNGAL can be used as an early marker to rule out AKI occurring within 3 days after major abdominal surgery. Intraoperative diuresis can be used to rule out AKI occurring up to 6 hours after surgery. TRIAL REGISTRATION: ISRCTN 53154834.
[Mh] Termos MeSH primário: Lesão Renal Aguda/sangue
Lesão Renal Aguda/urina
Diurese
Procedimentos Cirúrgicos em Ginecologia
Lipocalina-2/sangue
[Mh] Termos MeSH secundário: Algoritmos
Área Sob a Curva
Biomarcadores/sangue
Creatinina/sangue
Procedimentos Cirúrgicos de Citorredução
Diagnóstico Precoce
Feminino
Hemodinâmica
Seres Humanos
Período Intraoperatório
Laparotomia
Meia-Idade
Neoplasias Epiteliais e Glandulares/sangue
Neoplasias Epiteliais e Glandulares/cirurgia
Neoplasias Epiteliais e Glandulares/urina
Neoplasias Ovarianas/sangue
Neoplasias Ovarianas/cirurgia
Neoplasias Ovarianas/urina
Projetos Piloto
Fatores de Tempo
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Biomarkers); 0 (LCN2 protein, human); 0 (Lipocalin-2); AYI8EX34EU (Creatinine)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170730
[Lr] Data última revisão:
170730
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170713
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000007357


  5 / 12169 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28603109
[Au] Autor:Qureshi M; Mehjabeen -; Noorjahan -; Muhammad S; Siddiqui FA; Baig I; Ahmad M
[Ad] Endereço:Research Institute of Pharmaceutical Sciences, Faculty of Pharmacy, University of Karachi, Karachi, Pakistan.
[Ti] Título:Phytochemical and biological assessments on Lipidium meyenii (maca) and Epimidium sagittatum (horny goat weed).
[So] Source:Pak J Pharm Sci;30(1):29-36, 2017 Jan.
[Is] ISSN:1011-601X
[Cp] País de publicação:Pakistan
[La] Idioma:eng
[Ab] Resumo:The effects of Lipidium meyenii (maca, LM) and Epimidium sagittatum (horny goat weed, ES) have been investigated due to their involvement in fertilization. Both of the drugs showed good results before, during and after fertilization in male and female mice. The results revealed that the crude extract of Lipidium meyenii caused a significant decrease in the no. of writhes at 300 and 500mg/kg (p<0.05) as compare to control, Epimidium sagittatum and standard drug. The gross behavioral, open field, exploratory behaviour, forced swimming test for stress, diuretic activity, chronic toxicity with the effect on reproduction of both male and female and change in body weight were also studied. The phytochemical study showed the presence of tannin, alkaloid, carbohydrate, rich protein and absence of sterol in LM, whereas ES shows presence of sterol and less protein. LS improve in muscle activity and exploratory behaviours without any toxic effects on mice and their pups. It does not have diuretic effect for first two hour but act normally after initial phase of drug therapy. Epimidium sagittatum has dual action that is at low dose it has slight stimulation action and at high dose little depressive effect. ES also has some diuretic effect. Overall these results suggest that LM is highly effective remedy for treatment of impotency and reduces stress and depression, because of dual effect ES not only suggested as an anxiolytic medicine but also effective in female hormonal disorder.
[Mh] Termos MeSH primário: Ansiolíticos/farmacologia
Antidepressivos/farmacologia
Comportamento Animal/efeitos dos fármacos
Epimedium/química
Fármacos para a Fertilidade/farmacologia
Fertilidade/efeitos dos fármacos
Lepidium/química
Compostos Fitoquímicos/farmacologia
Extratos Vegetais/farmacologia
[Mh] Termos MeSH secundário: Ácido Acético
Analgésicos/isolamento & purificação
Analgésicos/farmacologia
Animais
Ansiolíticos/isolamento & purificação
Ansiolíticos/toxicidade
Antidepressivos/isolamento & purificação
Antidepressivos/toxicidade
Modelos Animais de Doenças
Diurese/efeitos dos fármacos
Diuréticos/isolamento & purificação
Diuréticos/farmacologia
Feminino
Fármacos para a Fertilidade/isolamento & purificação
Fármacos para a Fertilidade/toxicidade
Masculino
Atividade Motora/efeitos dos fármacos
Dor/induzido quimicamente
Dor/fisiopatologia
Dor/prevenção & controle
Limiar da Dor/efeitos dos fármacos
Compostos Fitoquímicos/isolamento & purificação
Compostos Fitoquímicos/toxicidade
Fitoterapia
Extratos Vegetais/isolamento & purificação
Extratos Vegetais/toxicidade
Plantas Medicinais
Comportamento Social
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Analgesics); 0 (Anti-Anxiety Agents); 0 (Antidepressive Agents); 0 (Diuretics); 0 (Fertility Agents); 0 (Phytochemicals); 0 (Plant Extracts); Q40Q9N063P (Acetic Acid)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171103
[Lr] Data última revisão:
171103
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170613
[St] Status:MEDLINE


  6 / 12169 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28566500
[Au] Autor:Li J; Hatano R; Xu S; Wan L; Yang L; Weinstein AM; Palmer L; Wang T
[Ad] Endereço:Department of Cellular and Molecular Physiology, Yale University, New Haven, Connecticut.
[Ti] Título:Gender difference in kidney electrolyte transport. I. Role of AT receptor in thiazide-sensitive Na -Cl cotransporter activity and expression in male and female mice.
[So] Source:Am J Physiol Renal Physiol;313(2):F505-F513, 2017 Aug 01.
[Is] ISSN:1522-1466
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:We studied gender differences in Na -Cl cotransporter (NCC) activity and expression in wild-type (WT) and AT receptor knockout (KO) mice. In renal clearance experiments, urine volume (UV), glomerular filtration rate, absolute Na (E ) and K (E ), and fractional Na (FE ) and K excretion were measured and compared at peak changes after bolus intravenous injection of hydrochlorothiazide (HCTZ; 30 mg/kg). In WT, females responded more strongly than males to HCTZ, with larger fractional increases of UV (7.8- vs. 3.4-fold), E (11.7- vs. 5.7-fold), FE (7.9- vs. 4.9-fold), and E (2.8- vs. 1.4-fold). In contrast, there were no gender differences in the responses to the diuretic in KO mice; HCTZ produced greater effects on male KO than on WT but similar effects on females. In WT, total (tNCC) and phosphorylated (pNCC) NCC protein expressions were 1.8- and 4.6-fold higher in females compared with males ( < 0.05), consistent with the larger response to HCTZ. In KO mice, tNCC and pNCC increased significantly in males to levels not different from those in females. There were no gender differences in the expression of the Na /H exchanger (NHE3) in WT; NHE3 protein decreased to similar extents in male and female KO animals, suggesting AT -mediated NHE3 expression in proximal tubules. The resulting increase in delivery of NaCl to the distal nephron may underlie increased NCC expression and activity in mice lacking the AT receptor.
[Mh] Termos MeSH primário: Angiotensina II/metabolismo
Receptor Tipo 1 de Angiotensina/metabolismo
Caracteres Sexuais
Trocadores de Sódio-Hidrogênio/metabolismo
[Mh] Termos MeSH secundário: Animais
Diurese
Feminino
Hidroclorotiazida
Rim/metabolismo
Masculino
Camundongos Knockout
Natriurese
Fenótipo
Proteínas Serina-Treonina Quinases/metabolismo
Receptor Tipo 1 de Angiotensina/genética
Receptores de Droga/metabolismo
Simportadores de Cloreto de Sódio/metabolismo
Trocador 3 de Sódio-Hidrogênio
Membro 3 da Família 12 de Carreador de Soluto/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Receptor, Angiotensin, Type 1); 0 (Receptors, Drug); 0 (Slc12a3 protein, mouse); 0 (Slc9a3 protein, mouse); 0 (Sodium Chloride Symporters); 0 (Sodium-Hydrogen Exchanger 3); 0 (Sodium-Hydrogen Exchangers); 0 (Solute Carrier Family 12, Member 3); 0 (thiazide receptor); 0J48LPH2TH (Hydrochlorothiazide); 11128-99-7 (Angiotensin II); EC 2.7.1.- (Prkwnk4 protein, mouse); EC 2.7.1.- (Stk39 protein, mouse); EC 2.7.11.1 (Protein-Serine-Threonine Kinases)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170602
[St] Status:MEDLINE
[do] DOI:10.1152/ajprenal.00087.2017


  7 / 12169 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28507171
[Au] Autor:Hunter RW; Moorhouse R; Farrah TE; MacIntyre IM; Asai T; Gallacher PJ; Kerr D; Melville V; Czopek A; Morrison EE; Ivy JR; Dear JW; Bailey MA; Goddard J; Webb DJ; Dhaun N
[Ad] Endereço:From the British Heart Foundation Centre of Research Excellence and The Queen's Medical Research Institute, University of Edinburgh, United Kingdom.
[Ti] Título:First-in-Man Demonstration of Direct Endothelin-Mediated Natriuresis and Diuresis.
[So] Source:Hypertension;70(1):192-200, 2017 Jul.
[Is] ISSN:1524-4563
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Endothelin (ET) receptor antagonists are potentially novel therapeutic agents in chronic kidney disease and resistant hypertension, but their use is complicated by sodium and water retention. In animal studies, this side effect arises from ET receptor blockade in the renal tubule. Previous attempts to determine whether this mechanism operates in humans have been confounded by the hemodynamic consequences of ET receptor stimulation/blockade. We aimed to determine the effects of ET signaling on salt transport in the human nephron by administering subpressor doses of the ET-1 precursor, big ET-1. We conducted a 2-phase randomized, double-blind, placebo-controlled crossover study in 10 healthy volunteers. After sodium restriction, subjects received either intravenous placebo or big ET-1, in escalating dose (≤300 pmol/min). This increased plasma concentration and urinary excretion of ET-1. Big ET-1 reduced heart rate (≈8 beats/min) but did not otherwise affect systemic hemodynamics or glomerular filtration rate. Big ET-1 increased the fractional excretion of sodium (from 0.5 to 1.0%). It also increased free water clearance and tended to increase the abundance of the sodium-potassium-chloride cotransporter (NKCC2) in urinary extracellular vesicles. Our protocol induced modest increases in circulating and urinary ET-1. Sodium and water excretion increased in the absence of significant hemodynamic perturbation, supporting a direct action of ET-1 on the renal tubule. Our data also suggest that sodium reabsorption is stimulated by ET-1 in the thick ascending limb and suppressed in the distal renal tubule. Fluid retention associated with ET receptor antagonist therapy may be circumvented by coprescribing potassium-sparing diuretics.
[Mh] Termos MeSH primário: Endotelina-1
Insuficiência Renal Crônica
Sódio/metabolismo
[Mh] Termos MeSH secundário: Adulto
Animais
Diurese/efeitos dos fármacos
Diurese/fisiologia
Método Duplo-Cego
Antagonistas dos Receptores de Endotelina/administração & dosagem
Antagonistas dos Receptores de Endotelina/efeitos adversos
Antagonistas dos Receptores de Endotelina/farmacocinética
Endotelina-1/administração & dosagem
Endotelina-1/efeitos adversos
Endotelina-1/farmacocinética
Feminino
Taxa de Filtração Glomerular
Seres Humanos
Túbulos Renais/metabolismo
Túbulos Renais/fisiopatologia
Masculino
Natriurese/efeitos dos fármacos
Natriurese/fisiologia
Receptores de Endotelina/metabolismo
Insuficiência Renal Crônica/tratamento farmacológico
Insuficiência Renal Crônica/metabolismo
Insuficiência Renal Crônica/fisiopatologia
Resultado do Tratamento
Equilíbrio Hidroeletrolítico/efeitos dos fármacos
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE II; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Endothelin Receptor Antagonists); 0 (Endothelin-1); 0 (Receptors, Endothelin); 9NEZ333N27 (Sodium)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170824
[Lr] Data última revisão:
170824
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170517
[St] Status:MEDLINE
[do] DOI:10.1161/HYPERTENSIONAHA.116.08832


  8 / 12169 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28299764
[Au] Autor:Zomorrodi A; Mohammadipoor Anvari H; Kakaei F; Solymanzadeh F; Khanlari E; Bagheri A
[Ad] Endereço:Department of Urology, Emam Reza Hospital, Tabriz University of Medical Sciences, Tabriz, Iran.
[Ti] Título:Bolus Injection Versus Infusion of Furosemide in Kidney Transplantation: A Randomized Clinical Trial.
[So] Source:Urol J;14(2):3013-3017, 2017 Mar 16.
[Is] ISSN:1735-546X
[Cp] País de publicação:Iran
[La] Idioma:eng
[Ab] Resumo:PURPOSE: Furosemide is commonly administered to increase the urinary output in patients with transplanted kidneys. This study compared the two administration routes of furosemide (bolus versus infusion) in kidney transplanted patients. MATERIALS AND METHODS: Fifty patients who had undergone kidney transplantation in 2015 in a hospital in Tabriz, Iran, were included in this clinical trial. They were divided into two groups: bolus (120 mg stat) and infusion (4 mg/minute) groups. The primary outcome was urine onset time. Secondary outcomes were urine output volume, vital signs (blood pressure, heart rate), and electrolyte level (creatinine, blood urea nitrogen, sodium and potassium). After arterial and venous anastomoses, arterial clamp removal time and diuresis onset were recorded. Finally, theurinary output volumes of both groups were measured with regular urine bags for an hour after anastomosis. Then it was repeated each three hours for 24 hours, and eventually two and three days thereafter. Finally, all data were statistically analyzed. RESULTS: Around 72% of the patients were men (mean age of 37.15 ± 14.67 years). Urine output was higher in bolus group but it was not statistically significant. Diuresis duration was measured after arterial declamping and its averages were 5.41 ± 3.7 minutes and 9.36 ± 7.65 minutes in bolus and infusion groups, respectively (P = .040). Furosemide bolus injection and infusion had no significant effect on creatinine, blood urea nitrogen, sodium and potassium. CONCLUSION: Furosemide bolus injection can reduce diuresis onset time compared to furosemide infusion.
[Mh] Termos MeSH primário: Diurese/efeitos dos fármacos
Diuréticos/administração & dosagem
Furosemida/administração & dosagem
[Mh] Termos MeSH secundário: Adulto
Pressão Sanguínea/efeitos dos fármacos
Feminino
Frequência Cardíaca/efeitos dos fármacos
Seres Humanos
Infusões Intravenosas
Injeções Intravenosas
Transplante de Rim
Masculino
Meia-Idade
Cuidados Pós-Operatórios
Fatores de Tempo
Urina
Adulto Jovem
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Diuretics); 7LXU5N7ZO5 (Furosemide)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171019
[Lr] Data última revisão:
171019
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170317
[St] Status:MEDLINE


  9 / 12169 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28228057
[Au] Autor:Michaud CJ; Mintus KC
[Ad] Endereço:1 Spectrum Health, Grand Rapids, MI, USA.
[Ti] Título:Intravenous Chlorothiazide Versus Enteral Metolazone to Augment Loop Diuretic Therapy in the Intensive Care Unit.
[So] Source:Ann Pharmacother;51(4):286-292, 2017 Apr.
[Is] ISSN:1542-6270
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: In cases of loop diuretic resistance in the intensive care unit (ICU), recommendations for a specific second-line thiazide agent are lacking. OBJECTIVE: To compare the effects of intravenous chlorothiazide (CTZ) and enteral metolazone (MET) on urine output (UOP) when added to furosemide monotherapy therapy in critically ill adults. METHODS: This was a retrospective cohort study conducted in the medical, surgical, and cardiothoracic ICUs of a quaternary medical center. The primary outcome was change in UOP induced by the study interventions compared with furosemide alone. Secondary outcomes included onset of diuresis, eventual need for hemodialysis, and incidence of adverse events. RESULTS: A total of 122 patients (58 in CTZ, 64 in MET) were included. When added to furosemide monotherapy, CTZ induced a greater change in UOP at 24 hours compared with MET (2405 vs 1646 mL, respectively; P = 0.01). CTZ also caused a more rapid dieresis: 1463 mL total UOP in the first 6 hours compared with 796 mL in the MET group ( P < 0.01). There were no differences found regarding ICU length of stay, need for renal replacement therapy, or survival to discharge. The CTZ arm required more potassium supplementation to maintain normokalemia (median 100 vs 57 mEq in MET; P = 0.02) and carried a higher cost (mean $97 vs $8, P < 0.01). CONCLUSION: Both CTZ and MET induced significant increases in UOP. CTZ induced a greater and more rapid change and was associated with higher cost and greater need for potassium replacement. Randomized controlled trials are needed to establish whether a preferable thiazide diuretic exists in this setting.
[Mh] Termos MeSH primário: Clorotiazida/uso terapêutico
Diurese/efeitos dos fármacos
Unidades de Terapia Intensiva
Metolazona/uso terapêutico
Inibidores de Simportadores de Cloreto de Sódio e Potássio/uso terapêutico
[Mh] Termos MeSH secundário: Administração Intravenosa
Administração Oral
Adulto
Clorotiazida/administração & dosagem
Clorotiazida/efeitos adversos
Estado Terminal
Quimioterapia Combinada
Feminino
Furosemida/administração & dosagem
Furosemida/efeitos adversos
Furosemida/uso terapêutico
Seres Humanos
Masculino
Metolazona/administração & dosagem
Metolazona/efeitos adversos
Estudos Retrospectivos
Inibidores de Simportadores de Cloreto de Sódio e Potássio/administração & dosagem
Inibidores de Simportadores de Cloreto de Sódio e Potássio/efeitos adversos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Sodium Potassium Chloride Symporter Inhibitors); 77W477J15H (Chlorothiazide); 7LXU5N7ZO5 (Furosemide); TZ7V40X7VX (Metolazone)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170811
[Lr] Data última revisão:
170811
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170224
[St] Status:MEDLINE
[do] DOI:10.1177/1060028016683971


  10 / 12169 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28179254
[Au] Autor:Weinstein AM
[Ad] Endereço:Departments of Physiology and Biophysics and of Medicine, Weill Medical College of Cornell University, New York, New York alan@nephron.med.cornell.edu.
[Ti] Título:A mathematical model of the rat kidney: K -induced natriuresis.
[So] Source:Am J Physiol Renal Physiol;312(6):F925-F950, 2017 Jun 01.
[Is] ISSN:1522-1466
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:A model of the rat nephron (Weinstein. 308: F1098-F1118, 2015) has been extended with addition of medullary vasculature. Blood vessels contain solutes from the nephron model, plus additional species from the model of Atherton et al. ( 247: F61-F72, 1984), representing hemoglobin buffering. In contrast to prior models of the urine-concentrating mechanism, reflection coefficients for DVR are near zero. Model unknowns are initial proximal tubule pressures and flows, connecting tubule pressure, and medullary interstitial pressures and concentrations. The model predicts outer medullary (OM) interstitial gradients for Na , K , CO , and [Formula: see text], such that at OM-IM junction, the respective concentrations relative to plasma are 1.2, 3.0, 2.7, and 8.0; within IM, there is high urea and low [Formula: see text], with concentration ratios of 11 and 0.5 near the papillary tip. Quantitative similarities are noted between K and urea handling (medullary delivery and permeabilities). The model K gradient is physiologic, and the urea gradient is steeper due to restriction of urea permeability to distal collecting duct. Nevertheless, the predicted urea gradient is less than expected, suggesting reconsideration of proposals of an unrecognized reabsorptive urea flux. When plasma K is increased from 5.0 to 5.5 mM, Na and K excretion increase 2.3- and 1.3-fold, respectively. The natriuresis derives from a 3.3% decrease in proximal Na reabsorption and occurs despite delivery-driven increases in Na reabsorption in distal segments; kaliuresis derives from a 30% increase in connecting tubule Na delivery. Thus this model favors the importance of proximal over distal events in K -induced diuresis.
[Mh] Termos MeSH primário: Diurese
Capacidade de Concentração Renal
Modelos Biológicos
Néfrons/irrigação sanguínea
Néfrons/metabolismo
Potássio/metabolismo
Sódio/metabolismo
[Mh] Termos MeSH secundário: Animais
Bicarbonatos/metabolismo
Dióxido de Carbono/metabolismo
Concentração de Íons de Hidrogênio
Microcirculação
Potássio/sangue
Potássio/urina
Ratos
Circulação Renal
Eliminação Renal
Reabsorção Renal
Sódio/sangue
Sódio/urina
Ureia/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Bicarbonates); 142M471B3J (Carbon Dioxide); 8W8T17847W (Urea); 9NEZ333N27 (Sodium); RWP5GA015D (Potassium)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170808
[Lr] Data última revisão:
170808
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170210
[St] Status:MEDLINE
[do] DOI:10.1152/ajprenal.00536.2016



página 1 de 1217 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde